Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
Primary Purpose
Preeclampsia
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Aspirin
Sponsored by
About this trial
This is an interventional prevention trial for Preeclampsia focused on measuring preeclampsia, aspirin, prediction, intervention, PAPP-A, PIGF, sFlt
Eligibility Criteria
Inclusion Criteria:
- 1)Pregnant women assessed as at high risk of preeclampsia 2) live pregnancy 3) gestational weeks < 16 weeks 4) agree to randomized drug intervention studies 5) follow up regularly and obtain reliable pregnancy outcomes
Exclusion Criteria:
- 1)with severe fetal or chromosomal abnormalities 2) induced labor or spontaneous abortion due to social factors 3) absolute or relative contraindications to aspirin use (allergy to aspirin or other salicylate, or other ingredients of the drug;Acute gastrointestinal ulcer;Active bleeding;In patients with severe G6PD deficiency, acetylsalicylic acid may induce hemolysis or hemolytic anemia.Aspirin asthma)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
aspirin group
control group
Arm Description
aspirin,tablet,100/150mg per day,(BMI<30 100mg/d,BMI≥30 150mg/d),from pregnancy weeks<16 to 35 weeks or the day of delivery.
with no intervention
Outcomes
Primary Outcome Measures
the rate of preeclampsia
Hypertensive onset after 20 weeks of gestation is accompanied by proteinuria,or with thrombocytopenia, impaired liver function, renal insufficiency,pulmonary edema,headache without other explanation and so on.
the rate of hypertensive disorder during pregnancy
gestational hypertension, preeclampsia, chronic hypertension with preeclampsia, eclampsia, HELLP syndrome
the rate of placenta abruption
After 20 weeks of pregnancy, the placenta in its normal position is completely or partially removed from the uterine wall before delivery of the fetus
the rate of fetal growth restriction
The birth weight of the fetus is below two standard deviations of the average weight for the same gestational age or below the 10th percentile of normal weight for the same age
the rate of postpartum hemorrhage
Within 24 hours after the delivery of the fetus, the bleeding volume of vaginal delivery ≥500ml, cesarean delivery ≥1000ml
the time and type of delivery
gestational week, vaginal delivery and cesarean section
Secondary Outcome Measures
birth weight of newborn
macrosomia, normal weight, low birth weight
Apgar score for newborns
≥8;4-7,;≤3
the rate of Neonatal NICU occupancy rate
the day of NICU occupancy
Full Information
NCT ID
NCT04631627
First Posted
November 7, 2020
Last Updated
November 15, 2020
Sponsor
Peking Union Medical College Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04631627
Brief Title
Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
Official Title
A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
November 16, 2020 (Anticipated)
Primary Completion Date
December 30, 2021 (Anticipated)
Study Completion Date
August 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking Union Medical College Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study intends to adopt the method of multi-center prospective randomized controlled study. The aim of this study is to obtain localized excision values through a preeclampsia screening model established in early pregnancy, and to evaluate the efficacy of low-dose aspirin intervention for preeclampsia prevention in pregnant women at high risk of screening.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preeclampsia
Keywords
preeclampsia, aspirin, prediction, intervention, PAPP-A, PIGF, sFlt
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
1500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
aspirin group
Arm Type
Active Comparator
Arm Description
aspirin,tablet,100/150mg per day,(BMI<30 100mg/d,BMI≥30 150mg/d),from pregnancy weeks<16 to 35 weeks or the day of delivery.
Arm Title
control group
Arm Type
Sham Comparator
Arm Description
with no intervention
Intervention Type
Drug
Intervention Name(s)
Aspirin
Intervention Description
With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
Primary Outcome Measure Information:
Title
the rate of preeclampsia
Description
Hypertensive onset after 20 weeks of gestation is accompanied by proteinuria,or with thrombocytopenia, impaired liver function, renal insufficiency,pulmonary edema,headache without other explanation and so on.
Time Frame
through study completion, an average of 1 year
Title
the rate of hypertensive disorder during pregnancy
Description
gestational hypertension, preeclampsia, chronic hypertension with preeclampsia, eclampsia, HELLP syndrome
Time Frame
through study completion, an average of 1 year
Title
the rate of placenta abruption
Description
After 20 weeks of pregnancy, the placenta in its normal position is completely or partially removed from the uterine wall before delivery of the fetus
Time Frame
through study completion, an average of 1 year
Title
the rate of fetal growth restriction
Description
The birth weight of the fetus is below two standard deviations of the average weight for the same gestational age or below the 10th percentile of normal weight for the same age
Time Frame
through study completion, an average of 1 year
Title
the rate of postpartum hemorrhage
Description
Within 24 hours after the delivery of the fetus, the bleeding volume of vaginal delivery ≥500ml, cesarean delivery ≥1000ml
Time Frame
within 24 hours after the delivery
Title
the time and type of delivery
Description
gestational week, vaginal delivery and cesarean section
Time Frame
within 24 hours after the delivery
Secondary Outcome Measure Information:
Title
birth weight of newborn
Description
macrosomia, normal weight, low birth weight
Time Frame
delivery time
Title
Apgar score for newborns
Description
≥8;4-7,;≤3
Time Frame
delivery time
Title
the rate of Neonatal NICU occupancy rate
Description
the day of NICU occupancy
Time Frame
through study completion, an average of 1 year
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
gestational women
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
1)Pregnant women assessed as at high risk of preeclampsia 2) live pregnancy 3) gestational weeks < 16 weeks 4) agree to randomized drug intervention studies 5) follow up regularly and obtain reliable pregnancy outcomes
Exclusion Criteria:
1)with severe fetal or chromosomal abnormalities 2) induced labor or spontaneous abortion due to social factors 3) absolute or relative contraindications to aspirin use (allergy to aspirin or other salicylate, or other ingredients of the drug;Acute gastrointestinal ulcer;Active bleeding;In patients with severe G6PD deficiency, acetylsalicylic acid may induce hemolysis or hemolytic anemia.Aspirin asthma)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jinsong Gao, PhD
Phone
18601106857
Ext
69155810
Email
gaojsong@163.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
The aim of this study was to obtain localized excision values through a preeclampsia screening model established in early pregnancy, and to evaluate the efficacy of low-dose aspirin intervention for preeclampsia prevention in pregnant women at high risk of screening.
IPD Sharing Time Frame
31 June, 2022
Citations:
PubMed Identifier
19464502
Citation
Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009 Jun;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010.
Results Reference
background
PubMed Identifier
25103301
Citation
Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5.
Results Reference
background
PubMed Identifier
24150027
Citation
Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88. No abstract available.
Results Reference
background
PubMed Identifier
22906914
Citation
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15. doi: 10.1159/000341264. Epub 2012 Aug 16. Erratum In: Fetal Diagn Ther. 2013;34(1):43.
Results Reference
background
PubMed Identifier
25678383
Citation
Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, Leung C, Saaid R, Rawashdeh H, Ogle R, Hyett J. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015 Oct;46(4):419-23. doi: 10.1002/uog.14819. Epub 2015 Aug 31.
Results Reference
background
PubMed Identifier
29239588
Citation
Sentilhes L, Azria E, Schmitz T. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Dec 14;377(24):2399-400. doi: 10.1056/NEJMc1713798. No abstract available.
Results Reference
background
PubMed Identifier
30710362
Citation
FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: First trimester screening and prevention of pre-eclampsia in singleton pregnancy. Int J Gynaecol Obstet. 2019 Mar;144(3):325-329. doi: 10.1002/ijgo.12741. No abstract available.
Results Reference
background
PubMed Identifier
30797761
Citation
Wright D, Nicolaides KH. Aspirin delays the development of preeclampsia. Am J Obstet Gynecol. 2019 Jun;220(6):580.e1-580.e6. doi: 10.1016/j.ajog.2019.02.034. Epub 2019 Feb 21.
Results Reference
background
Learn more about this trial
Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
We'll reach out to this number within 24 hrs